Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03097029 | Use of Pancreatic Enzymes in Short Bowel Syndrome | PHASE2 | COMPLETED | 16 | — | — | Mar 24, 2017 | Feb 1, 2019 | Mar 20, 2020 | 1 | United States |
Coefficient of fat absorption (CFA) measures the amount of fat excreted in the stool compared to how much fat was consumed over the course of 72 hours. This is a measure of fat absorption. CFA was measured at baseline off of pancreatic enzymes and then again while on ten days of pancreatic enzyme supplementation. The change between CFA values at each timepoint was the primary outcome.
| Arm | Type | Description |
|---|---|---|
| Pancreatic Enzymes | EXPERIMENTAL | All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days. |
| Name | Type | Description |
|---|---|---|
| Pancreatic Enzyme | DRUG | All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients. |
Inclusion Criteria: * history of a small bowel resection with subsequent dependence on parenteral nutrition for at least three months * age 4 years to 65 years * usual state of health for the past two weeks with no medication changes * able to participate in a study for about four weeks with four s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Teduglutide |
| Jaguar Health, Inc. | JAGX | 1 | PHASE2 | Crofelemer for |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | — | Undisclosed |